Page last updated: 2024-09-03

pre 084 and xanomeline

pre 084 has been researched along with xanomeline in 1 studies

Compound Research Comparison

Studies (pre 084)	Trials (pre 084)	Recent Studies (post-2010) (pre 084)	Studies (xanomeline)	Trials (xanomeline)	Recent Studies (post-2010) (xanomeline)
116	0	73	124	16	41

Protein Interaction Comparison

Protein	Taxonomy	xanomeline (IC50)
Muscarinic acetylcholine receptor M2	Homo sapiens (human)	0.1644
Muscarinic acetylcholine receptor M4	Homo sapiens (human)	0.0251
Muscarinic acetylcholine receptor M1	Homo sapiens (human)	1.3967

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Givalois, L; Kim, SH; Lahmy, V; Malmström, S; Maurice, T; Meunier, J; Naert, G; Vamvakides, A; Villard, V	1

Other Studies

1 other study(ies) available for pre 084 and xanomeline

Article	Year
Blockade of Tau hyperphosphorylation and Aβ₁₋₄₂ generation by the aminotetrahydrofuran derivative ANAVEX2-73, a mixed muscarinic and σ₁ receptor agonist, in a nontransgenic mouse model of Alzheimer's disease. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2013, Volume: 38, Issue:9 Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Dose-Response Relationship, Drug; Furans; Glycogen Synthase Kinase 3; Hippocampus; Infusions, Intraventricular; Male; Memory Disorders; Mice; Morpholines; Muscarinic Agonists; Neuroprotective Agents; Oxadiazoles; Peptide Fragments; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pyridines; Receptors, sigma; Signal Transduction; tau Proteins; Thiadiazoles	2013

Article

Year

Blockade of Tau hyperphosphorylation and Aβ₁₋₄₂ generation by the aminotetrahydrofuran derivative ANAVEX2-73, a mixed muscarinic and σ₁ receptor agonist, in a nontransgenic mouse model of Alzheimer's disease.

Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2013, Volume: 38, Issue:9

Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Dose-Response Relationship, Drug; Furans; Glycogen Synthase Kinase 3; Hippocampus; Infusions, Intraventricular; Male; Memory Disorders; Mice; Morpholines; Muscarinic Agonists; Neuroprotective Agents; Oxadiazoles; Peptide Fragments; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pyridines; Receptors, sigma; Signal Transduction; tau Proteins; Thiadiazoles

2013